Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03508752 : Neurocognitive Decline in Patients With Brain Metastases
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 120 Years
Eligibility
Inclusion Criteria:

- Age = 18 years.

- ECOG Performance Score of 2 or better.

- Biopsy-proven non-hematopoietic malignancy, except for germ cell cancer. Small cell
lung carcinoma is eligible for this study

- Six or more metastases on diagnostic or treatment planning imaging, which include
either CT or MR imaging.

- Largest tumor <4 cm

- No prior SRS to the lesions which will be treated on protocol.

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, and
for the duration of protocol treatment.

- Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

- Prior whole brain radiotherapy

- Patients with leptomeningeal metastasis.

- Patients with life expectancy < 4 months

- Psychiatric illness/social situations that would limit compliance with study
requirements.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03508752      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740